Johnson & Johnson's (JNJ) Janssen-Cilag International said Monday it received European Commission approval for its subcutaneous formulation of Rybrevant, or amivantamab, in two indications.
The subcutaneous formulation was approved in combination with lazertinib as the first-line treatment for advanced EGFR-mutated non-small cell lung cancer, and as a monotherapy for patients with EGFR exon 20 insertion mutations after platinum-based therapy failure, the company said.
The company said subcutaneous amivantamab was formulated using Halozyme Therapeutics' (HALO) drug delivery technology.
Johnson & Johnson said the approval follows positive results from a phase 3 study, which achieved its primary endpoints and indicated that subcutaneous amivantamab was "non-inferior" to the intravenous formulation in terms of efficacy and pharmacokinetics.
Johnson & Johnson shares were down nearly 3% in recent Monday trading, while Halozyme stock was up more than 2%.
Price: 148.75, Change: -4.50, Percent Change: -2.93
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。